Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.74 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31690894 | 1.00 | POLB (0.74) | POLBGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL5142574 | 0.91 | POLB (0.76) | POLBGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL5131103 | 0.87 | GAA (0.73) | POLBGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL13667856 | 0.85 | POLB (0.68) | POLBGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL31570067 | 0.85 | POLB (0.68) | POLBGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL17028020 | 0.85 | POLB (0.68) | POLBGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL4654355 | 0.85 | POLB (0.68) | POLBGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL26627737 | 0.84 | POLB (0.67) | POLBGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL11620710 | 0.83 | POLB (0.73) | POLBGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL14817539 | 0.83 | POLB (0.66) | POLBGAAKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656989-B2 | 2-pentafluorosulfanyl (SFS) mefloquine derivatives, formulations, methods of making, and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656989-B2 | 2-pentafluorosulfanyl (SFS) mefloquine derivatives, formulations, methods of making, and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| US-20160332988-A1 | 2-PENTAFLUOROSULFANYL (SF5) MEFLOQUINE DERIVATIVES, FORMULATIONS, METHODS OF MAKING, AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160332988-A1 | 2-PENTAFLUOROSULFANYL (SF5) MEFLOQUINE DERIVATIVES, FORMULATIONS, METHODS OF MAKING, AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2016-11-17 | — | — | US | disclosed |
| EP-1620391-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1656138-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1620391-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1617803-A2 | MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005020899-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| US-20040235835-A1 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| WO-2004098516-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004098512-A2 | MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235836-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | POLB 1862/4885GAA 4566/4885KMT2A 4466/4885 |
| US-20040235835-A1 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | POLB 3556/4885GAA 2249/4885KMT2A 3157/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | POLB 1325/4885GAA 1146/4885KMT2A 3391/4885 |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | POLB 1793/4885GAA 2532/4885KMT2A 2894/4885 |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | POLB 2084/4885GAA 4005/4885KMT2A 4093/4885 |
| US-20160332988-A1 | 2-PENTAFLUOROSULFANYL (SF5) MEFLOQUINE DERIVATIVES, FORMULATIONS, METHODS OF MAKING, AND USES THEREOF | SF3B5, SF3B2, SF3B3 | POLB 3558/4885GAA 3795/4885KMT2A 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.